arrow
R

Robin Ray

university of east london
H指数:22
被引数:3,767

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: insights from the IRONMAN trial
HEART
IF4.4
2025-02-120
PRE
Assessment of frailty in patients with heart failure: A new Heart Failure Frailty Score developed by Delphi consensus

心力衰竭患者虚弱的评估: 由Delphi共识开发的新的心力衰竭虚弱评分

2025-02-040
OA
Effect of correcting iron deficiency on the risk of serious infection in heart failure: Insights from the IRONMAN trial
2024-10-250
OA
Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the Heart Failure Association of the ESC

女性心力衰竭的表现,诊断和管理的差异。ESC心力衰竭协会的科学声明

2024-05-234
OAAI
How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC

如何应对射血分数降低的心力衰竭的治疗惯性。ESC心力衰竭协会的科学声明

2024-05-229
OA
The Impact of Ferric Derisomaltose on Cardiovascular and Noncardiovascular Events in Patients With Anemia, Iron De ficiency, and Heart Failure With Reduced Ejection Fraction
2024-05-012
OAAI
Multidisciplinary care of peripartum heart failure: A scientific statement of the Heart Failure Association of the ESC

围产期心力衰竭的多学科护理: ESC心力衰竭协会的科学声明

2024-04-283
PRE
Effect of intravenous iron (ferric derisomaltose) on haemoglobin and clinical events according to age in patients with heart failure and iron deficiency in a randomised trial (ironman)

在一项随机试验 (ironman) 中,根据年龄,静脉注射铁 (异麦芽糖铁) 对心力衰竭和铁缺乏患者的血红蛋白和临床事件的影响

HEART
IF4.4
2023-06-020
OA
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN) : an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial

英国心力衰竭和铁缺乏患者的静脉注射铁异麦芽糖 (IRONMAN): 研究者发起的,前瞻性,随机,开放标签,盲法终点试验

LANCET
IF88.5
2022-12-01188
OAAI
Education and certification on heart failure of the Heart Failure Association of the European Society of Cardiology
2022-01-236
OA
COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology
2021-12-0541
OA
Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure (an update on the sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology)

欧洲心脏病学会心力衰竭协会关于心力衰竭中钠-葡萄糖共转运蛋白2抑制剂的更新 (关于心力衰竭中钠-葡萄糖共转运蛋白2抑制剂的更新: 超越血糖控制。欧洲心脏病学会心力衰竭协会的立场文件)

2020-10-2771
OAAI
Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology

心力衰竭中的钠-葡萄糖共转运蛋白2抑制剂: 超越血糖控制。欧洲心脏病学会心力衰竭协会的立场文件

2020-08-05105
OA